Oncotelic Therapeutics, Inc.’s Joint Venture, Sapu Nano, revealed new biomarker data at the 2025 San Antonio Breast Cancer Symposium showing a molecular signature predicting sensitivity to their IV everolimus formulation, Sapu003. Tumors with High-RICTOR / Low-RPTOR gene-expression pattern are more likely to respond to Sapu003, especially in breast, lung, gastric, renal, ovarian cancers, AML, and T-cell malignancies. Sapu003’s IV delivery overcomes limitations of oral everolimus, offering precise patient selection for mTOR therapy.

Sapu Nano’s Chief Medical Officer, Dr. Seymour Fein, highlighted the significance of the High-RICTOR / Low-RPTOR signature as a breakthrough in targeting patients most likely to benefit from mTOR inhibition. The biomarker analysis, showcased at the SABCS, offers a strategic approach to mTOR therapy, with Sapu003 providing effective treatment for patients with the identified signature across multiple datasets. The innovative IV delivery system of Sapu003 addresses the challenges associated with oral everolimus, enabling personalized treatment for mTOR-driven cancers.

Read more at GlobeNewswire: Oncotelic and Sapu Nano Announce DeciparticleTM Led